首页> Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer> Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.

Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.

导出原文传递

翻译打印收藏纠错

第一作者： Mauricio,Burotto

第一单位： Centro de Investigación, Clínica Bradford Hill, Santiago, Chile. Electronic address: Mburotto@bradfordhill.cl.

作者： Mauricio,Burotto ^[1] ; Zanete,Zvirbule ^[2] ; Renzo,Alvarez ^[3] ; Busayamas,Chewaskulyong ^[4] ; Luis A,Herraez-Baranda ^[5] ; Esther,Shearer-Kang ^[6] ; Xiaoyan,Liu ^[6] ; Nadia,Tosti ^[5] ; Patrick,Williams ^[6] ; Amparo Yovanna,Castro Sanchez ^[5] ; James,Zanghi ^[6] ; Enriqueta,Felip ^[7]

作者单位： Centro de Investigación, Clínica Bradford Hill, Santiago, Chile. Electronic address: Mburotto@bradfordhill.cl. ^[1] Riga Eastern Clinical University Hospital, Rīga, Latvia. ^[2] Centro Médico Monte Carmelo, Arequipa, Peru. ^[3] Chiang Mai University, Chiang Mai, Thailand. ^[4] F. Hoffmann-La Roche Ltd, Basel, Switzerland. ^[5] Genentech, Inc., South San Francisco, California. ^[6] Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain. ^[7]

关键词 Atezolizumab IMscin001 Intravenous NSCLC Subcutaneous